Vladimirova-Kitova Lyudmila G, Deneva Tania I, Nikolov Fedya P
Clinic of Cardiology, Department of Clinical Laboratory, Medical University, Plovdiv, Bulgaria.
Folia Med (Plovdiv). 2011 Apr-Jun;53(2):13-21.
The effect of statins on the levels of cell adhesion molecules (CAM) is discussed in the literature as one of the pleiotropic effects of the drugs. This effect is one of the ways that could be used to control the initial stage of atherogenesis. The research in this field is inadequate and controversial. Prevention guidelines recommend that target levels of LDL cholesterol in high-risk patients should be less than 2.6 mmol/l. If the primary target is LDL-cholesterol, it is doubtful if patients can have any significant changes in the levels of the cell adhesion molecules (CAM).
Study the effect of simvastatin administered in a moderate dose of 40 mg and in a high dose of 80 mg on endothelium activation in the context of the plasma levels of soluble cellular adhesion molecules (sICAM-1, sVCAM-1, sE-selectin, sP-selectin) in recently diagnosed untreated severe hypercholesterolemia after reaching target levels for the LDL-cholesterol below 2.6 mmol/1.
One hundred patients (aged > 16 years) were included in the study. Hypercholesterolemia was defined as fasting total serum cholesterol level greater than 7.5 mmol/l and LDL-cholesterol > 4.9 mmol/l. The study was carried out in three phases, the main goal being titration of simvastatin dose from 40 to 80 mg with the purpose of achieving the target LDL level of < 2.6 mmol/l in a randomised placebo-controlled study.
There was a statistically significant reduction of sVCAM-1 following the 80-mg simvastatin therapy for one month after reaching target levels of LDL-cholesterol < 2.6 mmol/l in hypercholesterolemic patients in comparison with the moderate dose (40 mg) of simvastatin for one month (p < 0.001). The results of the study demonstrated that simvastatin in a dose of 80 mg exerted an effect on the levels of some CAM, and particularly on VCAM-1 in contrast to the same drug used in a dose of 40 mg.
As different statins most likely have a distinctly specific effect on different adhesion molecules, this study seeks to establish a suitable panel of such adhesion molecules that may be used in monitoring statin therapy.
他汀类药物对细胞黏附分子(CAM)水平的影响在文献中被作为该类药物的多效性作用之一进行了讨论。这种作用是可用于控制动脉粥样硬化发生初始阶段的途径之一。该领域的研究尚不充分且存在争议。预防指南建议高危患者的低密度脂蛋白胆固醇目标水平应低于2.6 mmol/l。如果主要目标是低密度脂蛋白胆固醇,那么患者的细胞黏附分子(CAM)水平是否会有显著变化就值得怀疑了。
研究在近期诊断出未经治疗的重度高胆固醇血症患者中,当低密度脂蛋白胆固醇达到低于2.6 mmol/1的目标水平后,给予40 mg中等剂量和80 mg高剂量辛伐他汀对内皮细胞活化的影响,同时观察可溶性细胞黏附分子(sICAM - 1、sVCAM - 1、sE - 选择素、sP - 选择素)的血浆水平变化。
100名年龄大于16岁的患者纳入研究。高胆固醇血症定义为空腹血清总胆固醇水平大于7.5 mmol/l且低密度脂蛋白胆固醇大于4.9 mmol/l。研究分三个阶段进行,主要目的是在一项随机安慰剂对照研究中,将辛伐他汀剂量从40 mg滴定至80 mg,以达到低密度脂蛋白目标水平<2.6 mmol/l。
在高胆固醇血症患者中,当低密度脂蛋白胆固醇达到<2.6 mmol/l的目标水平后,接受80 mg辛伐他汀治疗1个月后,与接受40 mg中等剂量辛伐他汀治疗1个月相比,sVCAM - 1有统计学显著降低(p < 0.001)。研究结果表明,80 mg剂量的辛伐他汀对某些CAM水平有影响,特别是对VCAM - 1的影响,与40 mg剂量的同一药物相比有所不同。
由于不同的他汀类药物很可能对不同的黏附分子有明显的特异性作用,本研究旨在确定一组合适的此类黏附分子,可用于监测他汀类药物治疗。